Moreover, genetic deletion of β-TrCP partially increases the viability of HepG2 cells with exposure of berberine, revealing that Cyclin D1 degradation induced by berberine may contribute partially to its anti-tumor activity. The gene discussed is BTRC; the disease is neoplasm.